Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 2Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1CNS 1

Conditions

Breast Neoplasms 1914Neoplasms 1533Prostatic Neoplasms 753Colorectal Neoplasms 715Lung Neoplasms 584Motor Activity 396Head and Neck Neoplasms 328Colonic Neoplasms 313Uterine Cervical Neoplasms 300Pain 248Pancreatic Neoplasms 246Anxiety Disorders 222Rectal Neoplasms 214Carcinoma, Hepatocellular 209Carcinoma, Non-Small-Cell Lung 206Fatigue 195Stomach Neoplasms 192Polycystic Ovary Syndrome 188Ovarian Neoplasms 186Precursor Cell Lymphoblastic Leukemia-Lymphoma 178Brain Neoplasms 170Depression 167Urinary Bladder Neoplasms 165Neoplasm Metastasis 163Melanoma 163Esophageal Neoplasms 140Multiple Myeloma 138Lymphoma 136Obesity 128Lymphoma, Follicular 128

Interventions

lenvatinib 1cabozantinib 1Restraint, Physical 1Absorptiometry, Photon 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Completed × Paraganglioma, Extra-Adrenal × Clear all
NCT02592356 2024-03-05

Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer

M.D. Anderson Cancer Center

Phase NA Completed
23 enrolled
CNSEndocrine

Paraganglioma, Extra-Adrenal, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡